Nov 20, 2010, 03.38 PM | Source: Moneycontrol.com
The IPO of Claris Lifesciences, a sterile injectables pharmaceutical company, is set to enter capital market for subscription on November 24, 2010.
The company aims to raise Rs 300 crore through IPO.
As per the draft prospectus, Claris is one of the largest Indian sterile injectables pharmaceutical companies with a presence in 76 countries worldwide. Products offering comprises 113 products across multiple markets and therapeutic areas. All of its products are off-patent products, a significant majority of which are capable of being directly injected into the body and are predominantly used in the treatment of critical illnesses.
Proceeds of the issue will be used for setting up of a new plant comprising a small volume parenterals line - a PVC bag line, a non-PVC bag line and a fat emulsion line. It will be used for setting up of a new manufacturing line for propofol and other fat emulsion products at existing plant in Clarion IV. The funds will also be used construction of a facility for research and development at Clarion manufacturing facilities; and prepayment of an identified term loan.
Enam Securities Private Limited, Edelweiss Capital Limited, JM Financial Consultants Private Limited and ICICI Securities Limited are the book running lead managers to the issue.
Drug firm Claris Lifesciences has received the Est
US drug regulator gives Establishment Information
"The US Food & Drug Administration has concluded t
Claris Lifesciences has submitted a copy of
After many flip-flops, it looks like tomorrow coul
Multi Commodity Exchange of India (MCX), country's
SP Tulsian of sptulsian.com tells CNBC-TV18 that h